Isaac Israel

Biotech entrepreneur, CEO of Purple Biotech (NASDAQ/TASE: $PPBT)

[Isaac Israel @isaac2199]

Happy to report the progress, looking forward!

[Purple Biotech @_PurpleBiotech]

We are thrilled to announce the initiation of the Phase 2 study for CM24 as a potential 2L treatment for patients with #PDAC, expanding the potential for treatment for #patients while extending our cash runway through 2024. More: https://t.co/Fq7PEDxoRy #oncology #cancer #PDAC

[Isaac Israel @isaac2199]

Sweet gift received in our office from Purple Biotech GmbH 🍫

[Isaac Israel @isaac2199]

Further, I would like to acknowledge our patients. Your strength and fortitude inspire and motivate us to create successful, long-lasting treatments for people with cancer.

[Isaac Israel @isaac2199]

I look back at 2021 proudly as a foundation-setting year for Purple Biotech, one with clinical development achievements, personnel and culture advancements. >>

[Purple Biotech @_PurpleBiotech]

We are pleased to issue the following letter from its Chief Executive Officer, Isaac Israel, to its shareholders: https://t.co/U1nW1k3gHp

#cancerresearch #curecancer #oncology

[Isaac Israel @isaac2199]

I want to acknowledge our shareholders, leadership, Board of Directors and employees. Throughout the past year, your support and efforts have directly contributed to the company, our position, and our future. >>

[Isaac Israel @isaac2199]

Happy to share our first cohort analysis of CM24 study, reinforcing our confidence in the potential of our CEACAM1 mAb to become a safe and effective cancer treatment. #PancreaticCancer #CancerResearch #ESMO21 #ceacam1

[Purple Biotech @_PurpleBiotech]

1/4 We are excited to provide an update about our ongoing Phase 1b/2 clinical trial of CM24 for the treatment of multiple advanced cancers #oncology #CancerResearch #PancreaticCancer https://t.co/i4yuCFAhvy

[Isaac Israel @isaac2199]

So encouraging to witness NT219 shrinking a tumor in the first dose level cohort of its ongoing Phase 1/2 clinical study. We expect to report additional data from higher dose levels of this study in the second half of this year. #ASCO21 #CancerResearch #oncology

[Purple Biotech @_PurpleBiotech]

Purple is excited to announce that NT219 was well-tolerated in initial clinical data from our ongoing Phase 1/2 study with a partial response observed in a patient with refractory GE junction cancer #CancerResearch #ASCO21 #Curecancer https://t.co/29wnQWu7Um

[Isaac Israel @isaac2199]

@PolishTrader_ Thank you, appreciate your support. I am sorry for your loss, we are inspired by stories like yours as we are committed to harness the most cutting-edge science to transform the lives of those who are fighting against the disease

[Isaac Israel @isaac2199]

Looking forward to the #ASCO21 Annual Meeting.
#oncology #cancer #cancerresearch

[Purple Biotech @_PurpleBiotech]

Purple Biotech to present interim data from our ongoing Phase 1/2 clinical trial of NT219, a monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers, on June 4 #ASCO21 #cancer #cancerresearch #oncologyresearch

[Isaac Israel @isaac2199]

Over the past few years, our business has evolved significantly towards an exciting new vision and our new name, Purple Biotech, completes the transformation to our focus on advancing first-in-class oncology therapies. Exciting 2021 lies ahead ahead of us!

[Isaac Israel @isaac2199]

Important new data presented as part of our collaboration with Prof. Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky MC. Kudus to the research team at TAU & TAMSC and to our great R&D team at Kitov!

[Purple Biotech @_PurpleBiotech]

Happy to present new data supporting NT219's MOA, a dual inhibitor, novel SM targeting IRS1/2 & STAT3 at the Epigenetics and Metabolism AACR Virtual Conference by researchers at TASMC & Tel-Aviv University #cancer #tasmc
https://t.co/KRhj1AKYVf

[Isaac Israel @isaac2199]

Very encouraging preclinical data, strongly suggest that the inhibition of the STAT3 and IRS-AKT pathways has the potential to address the tumor resistance phenotype. We look forward to initiating of the Phase 1/2 trial soon!

[Purple Biotech @_PurpleBiotech]

Proud to present the anti-tumor activity of NT219 in pembrolizumab-resistant head and neck cancer PDX models at AACR 2020 virtual meeting II #Cancer #AACR2020 #keytdura #oncology #headandneckcancer

[Isaac Israel @isaac2199]

@stocksnjocks1 @Kitov_Pharma Please DM me with your email address, I’ll make sure you get a quick response. BTW, you deserve it just like any SH, regardless the size of your position

[Isaac Israel @isaac2199]

Back in 2017 we acquired NT-219 as a first step in our long term strategy to transform Kitov into an innovative oncology company. Pleased to deliver this milestone. Looking forward to initiating the study, wish we can bring new hope for cancer patients with this promising agent!

[Purple Biotech @_PurpleBiotech]

We are glad to announce U.S. FDA IND acceptance to conduct a phase 1/2 clinical trial of NT-219 for treatment of recurrent or metastatic solid tumors and head and neck cancer. https://t.co/0mdtSRNKZD #cancer #headandneckcancer #solidtumors #clinicaltrials

[Isaac Israel @isaac2199]

Seven years of development have materialized into a great new treatment option now available for millions of patients suffering simultaneously from hypertension and osteoarthritis related pain. Very exciting moment!

[Purple Biotech @_PurpleBiotech]

Proud to announce the U.S. commercial launch of Consensi™, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi™ is being sold by Burke Therapeutics, the marketing partner of our distributor, Coeptis Pharmaceuticals. https://t.co/2rVjHIWNGr

[Isaac Israel @isaac2199]

@ProfitsWin Sorry, but can’t refer to the content of any future PR

[Isaac Israel @isaac2199]

@ProfitsWin See here (speaks for itself): https://t.co/5nkQ38qrAr

[Purple Biotech @_PurpleBiotech]

Proud to present today our expanded planned NT-219 clinical program for difficult to treat cancers, at the 2020 Multidisciplinary Head and Neck Cancers Symposium, being held in Scottsdale, Arizona #cancer #headandneckcancer #HNCS20